Safety of a picosecond laser with diffractive lens array (DLA) in the treatment of Fitzpatrick skin types IV to VI: A retrospective review - 14/04/16
Abstract |
Background |
Laser therapy in patients with skin of color is associated with an increased rate of complications. The 755-nm picosecond laser with the diffractive lens array (DLA) has been used for the treatment of scars, striae, and rejuvenation. By delivering high energy to focused areas, the DLA minimizes complications.
Objective |
This study explores the adverse events associated with treatment with the 755-nm picosecond laser with DLA in individuals with Fitzpatrick skin type IV to VI.
Method |
A retrospective chart review of patients treated with the 755-nm picosecond laser with DLA with a standardized spot size of 6 mm, fluence of 0.71 J/cm2, and pulse width of 750 to 850 picoseconds was performed. Standard clinical photographs were obtained before treatment and at follow-up. Treatment sites were assessed for dyspigmentation, erythema, edema, and herpetic lesions.
Results |
A total of 56 patients with Fitzpatrick skin type IV to VI, atrophic and hypertrophic scars, and pigmented lesions or striae were included. Ten patients (17.9%) were lost to follow-up. Transient adverse events, most commonly erythema and hyperpigmentation, were reported after therapy; these resolved in all cases.
Limitations |
Retrospective design is a limitation.
Conclusion |
The 755-nm picosecond laser with the DLA device may be a safe therapeutic alternative for unwanted scars, pigmented lesions, and striae in patients with skin of color.
Le texte complet de cet article est disponible en PDF.Key words : cutaneous laser, diffractive lens array, picosecond laser, postinflammatory hyperpigmentation, safety, skin of color
Abbreviations used : DLA, LIOB, PIH
Plan
| Funding sources: None. |
|
| Disclosure: Dr Brauer is a consultant for Miramar, received honoraria from Cynosure/Palomar, and is on the medical advisory board for Cynosure. Dr Bae is a consultant for BioSpecifics Technology and Allergan. Dr Geronemus received honoraria from Cynosure/Palomar; has stock ownership or options with Zeltiq and OnLight Sciences; and is on medical advisory boards for Zeltiq, Syneron/Candela, and Cynosure/Palomar. Dr Haimovic has no conflicts of interest to declare. |
Vol 74 - N° 5
P. 931-936 - mai 2016 Retour au numéro
Article précédent
- Perioral wrinkles are associated with female gender, aging, and smoking: Development of a gender-specific photonumeric scale
- Anna L. Chien, Ji Qi, Nancy Cheng, Thy Thy Do, Missale Mesfin, Robert Egbers, Wenfei Xie, Conroy Chow, Heather Chubb, Dana Sachs, John Voorhees, Sewon Kang
- Distinguishing diffuse alopecia areata (AA) from pattern hair loss (PHL) using CD3+ T cells
- Athanassios Kolivras, Curtis Thompson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?